74.16 May 20, 4:02PM EDT|Pre-Market
:
73.75 
0.41 (0.55%) 6:16AM EDT - Nasdaq Real Time Price
| Prev Close: | 74.16 |
|---|
| Open: | N/A |
|---|
| Bid: | 73.69 x 200 |
|---|
| Ask: | 73.77 x 200 |
|---|
| 1y Target Est: | 73.94 |
|---|
| Beta: | 0.55 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 51.20 - 75.67 |
|---|
| Volume: | 900 |
|---|
| Avg Vol (3m): | 1,574,130 |
|---|
| Market Cap: | 182.23B |
|---|
| P/E (ttm): | 18.82 |
|---|
| EPS (ttm): | 3.94 |
|---|
| Div & Yield: | 2.53 (3.40%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Johnson & Johnson Stock Checkup for Mayat Motley Fool(Tue 2:06AM EDT)
- Actavis, Warner Chilcott Stocks Rise On Merger Newsat Investor's Business Daily(Mon, May 20)
- Ireland Welcomes Watson Pharmaceuticals, an American Successat TheStreet(Mon, May 20)
- [$$] Actavis Prepares for Its Next Actat Barrons.com(Mon, May 20)
- Early Movers: YHOO, CPB, BA, GE & Moreat CNBC(Mon, May 20)
- Actavis to Buy Warner Chilcott in $5B Stock Dealat Fox Business(Mon, May 20)
- Multiple Sclerosis and Hemophilia: This Biotech's Just Getting Startedat Motley Fool(Sun, May 19)
- The 5 Richest Countries in the Worldat Motley Fool(Sun, May 19)
- Novartis AG (NVS): Today's Featured Drugs Laggardat TheStreet(Fri, May 17)
- 3 Companies That Put the "Tech" in "Biotech"at Motley Fool(Thu, May 16)
- Novartis says no intention of pursuing Actavis, Bloomberg reportstheflyonthewall.com(Thu, May 16)
- Early Movers: WMT, KSS, CSCO & Moreat CNBC(Thu, May 16)
- Morning Briefing: 10 Things You Should Knowat TheStreet(Thu, May 16)
- Angelina Jolie's Selfless Act Heightens Breast Cancer Awarenessat Motley Fool(Wed, May 15)
- Good News for Novartis' IlarisZacks(Wed, May 15)
Key Statistics
| Forward P/E (1 yr): | 13.71 |
|---|
| P/S (ttm): | 3.15 |
|---|
| Ex-Dividend Date: | 26-Feb-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 4.95 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.29 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 2.76 |
|---|
Business Summary
Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary...
View More